Regeneron to buy ‘substantially all’ of 23andMe’s assets for $256M

Regeneron Pharmaceuticals announced on Monday that it will get “all” of the 23ndem G’s Asset.

The pharmaceutical company said that it won the auction that was supervised in the court of the genetic test company, as Regeneron agreed to pay 256 million dollars to assets. 23andme was subjected to auction as part of the bankruptcy protection, Chapter 11, which I presented in March to facilitate the sale of his business.

In the bankruptcy petition, the company estimated a range of $ 100 million to $ 500 million for its assets. The estimated obligations were the same.

Regeneron said that the deal to buy 23ndme assets will be closed in the third quarter of 2025, provided that it obtains approval from the bankruptcy court that oversees the bankruptcy case of the genetic test company. The deal will be weight by the court in mid -June.

23ndme files for bankruptcy where California urging customers to delete data

The pharmaceutical company purchases the 23ndme Personal Service and its total sectors for health and research services, according to 23andme.

23DME said that the deal includes Regeneron’s commitment to compliance with the company’s privacy policies and the applicable law, and to process all the personal data of the customer in accordance with approval, privacy and data policies, conditions of service and notifications that are currently present and are security controls designed to protect these data. ”

“Through the Regeron Genetics Center, we have a busy record in protecting personal genetic data, and we assure 23andme customers that we will apply our high standards to safety and integrity to their continuous continuous genetic services,” George Yankopoulos, Chairman of the Regeneron Board of Directors, said in a statement.

Regeneron said that the deal to buy 23ndme assets will be closed in the third quarter of 2025. (Pavlo Gonchaar/SOPA Images/Lightrockket via Getty Images/Getty Images)

He added: “We believe that we can help 23andme to fulfill and build its mission to help people recognize their DNA and how to improve their personal health, while strengthening Regeneron’s efforts to improve health and wellness for many.”

23DME bankruptcy: Will your private data be protected?

23ndme said that one of the consumers appointed by the court will provide the grievance secretary in the court on a report on June 10 after the review of the proposed Regeneron for 23andme and “effect, if any, on the privacy of consumers.”

Regeneron wants to make 23andme a subsidiary “fully or indirect” company after purchase, with plans to maintain personal genome service.

23ndme said that one of the consumers appointed by the court will provide the grievance secretary in the court on a report on June 10 after the review of the proposed Regeneron for 23andme and “effect, if any, on the privacy of consumers.” (Smith Collection/GADO/Getty Images/Getty Images)

“We are pleased to reach a treatment that increases the value of the work and enables the task of 23andme to live on it, while maintaining critical protection on the customer’s privacy, choice and consent in relation to their genetic data.”

23andme corresponds to pay $ 30 million to settle a lawsuit on 2023 data breach

23andme also management of Lemonaid Health Health Health Health. This work, which is not bought by Regeneron.